ID   HF
AC   CVCL_UI84
DR   ATCC; CRL-3383
DR   Wikidata; Q94113023
RX   PubMed=20664054;
RX   PubMed=20889926;
RX   PubMed=29416618;
RX   PubMed=29666304;
CC   Population: Caucasian.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ATCC=CRL-3383
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11,13
ST   D16S539: 9,12
ST   D5S818: 11
ST   D7S820: 10,13
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 16
DI   NCIt; C36080; Diffuse large B-cell lymphoma germinal center B-cell type
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   77Y
CA   Cancer cell line
DT   Created: 25-02-19; Last updated: 02-05-24; Version: 6
//
RX   PubMed=20664054; DOI=10.1182/blood-2009-12-257378; PMCID=PMC2981542;
RA   Pham L.V., Tamayo A.T., Li C.-P., Bueso-Ramos C.E., Ford R.J. Jr.;
RT   "An epigenetic chromatin remodeling role for NFATc1 in transcriptional
RT   regulation of growth and survival genes in diffuse large B-cell
RT   lymphomas.";
RL   Blood 116:3899-3906(2010).
//
RX   PubMed=20889926; DOI=10.1182/blood-2010-06-290437; PMCID=PMC3037744;
RA   Pham L.V., Fu L.-C., Tamayo A.T., Bueso-Ramos C.E., Drakos E.,
RA   Vega-Vazquez F., Medeiros L.J., Ford R.J. Jr.;
RT   "Constitutive BR3 receptor signaling in diffuse, large B-cell
RT   lymphomas stabilizes nuclear factor-kappaB-inducing kinase while
RT   activating both canonical and alternative nuclear factor-kappaB
RT   pathways.";
RL   Blood 117:200-210(2011).
//
RX   PubMed=29416618; DOI=10.18632/oncotarget.20378; PMCID=PMC5787470;
RA   Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S.-H., Shen C.,
RA   Young K.H., Westin J., Davis R.E., Hu S.-M., Medeiros L.J., Ford R.J. Jr.,
RA   Pham L.V.;
RT   "Preclinical efficacy and biological effects of the oral proteasome
RT   inhibitor ixazomib in diffuse large B-cell lymphoma.";
RL   Oncotarget 9:346-360(2018).
//
RX   PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004;
RA   Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H.,
RA   Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H.,
RA   Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.;
RT   "Strategic therapeutic targeting to overcome venetoclax resistance in
RT   aggressive B-cell lymphomas.";
RL   Clin. Cancer Res. 24:3967-3980(2018).
//